within Pharmacolibrary.Drugs.ATC.J;

model J01GB11
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0014,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00023999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00011999999999999999,
    k12             = 3.6,
    k21             = 3.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01GB11</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Isepamicin is an aminoglycoside antibiotic, structurally related to gentamicin and amikacin, primarily used for the treatment of severe infections caused by Gram-negative bacteria. It was mainly developed and used in some Asian countries, but is not globally approved or widely available today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with normal renal function.</p><h4>References</h4><ol><li><p>Radwanski, E, et al., &amp; Lin, CC (1997). Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections. <i>Antimicrobial agents and chemotherapy</i> 41(8) 1794–1796. DOI:<a href=\"https://doi.org/10.1128/AAC.41.8.1794\">10.1128/AAC.41.8.1794</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9257763/\">https://pubmed.ncbi.nlm.nih.gov/9257763</a></p></li><li><p>Tod, M, et al., &amp; Petitjean, O (2000). Clinical pharmacokinetics and pharmacodynamics of isepamicin. <i>Clinical pharmacokinetics</i> 38(3) 205–223. DOI:<a href=\"https://doi.org/10.2165/00003088-200038030-00002\">10.2165/00003088-200038030-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10749517/\">https://pubmed.ncbi.nlm.nih.gov/10749517</a></p></li><li><p>Lin, C, et al., &amp; Cayen, MN (1995). Pharmacokinetics and metabolism of 14C-isepamicin in humans following intravenous administration. <i>Antimicrobial agents and chemotherapy</i> 39(10) 2201–2203. DOI:<a href=\"https://doi.org/10.1128/AAC.39.10.2201\">10.1128/AAC.39.10.2201</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8619567/\">https://pubmed.ncbi.nlm.nih.gov/8619567</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01GB11;
